# Hepatitis C - DAA Era Management

## Virology and Epidemiology

### Virology

Hepatitis C virus belongs to the Flaviviridae family and is a positive-sense, single-stranded RNA virus with a 9.6 kilobase genome. It encodes both structural proteins (core, E1, E2) and non-structural proteins (NS2, NS3/4A, NS4B, NS5A, NS5B). The direct-acting antiviral targets are NS3/4A (a serine protease), NS5A (a component of the replication complex), and NS5B (the RNA-dependent RNA polymerase).

A critical distinction from hepatitis B is that HCV has no DNA intermediate, meaning there is no integration into the host genome and no cccDNA equivalent. This makes true virologic cure, defined as sustained virologic response, achievable. The virus has a very high replication rate, producing approximately 10 to the 12th power virions per day, and its error-prone RNA polymerase generates extensive quasispecies diversity. There are 8 major genotypes (1 through 8), with genotype 1 being the most common in the United States at 70%. The development of pangenotypic DAA regimens has made genotyping less critical for treatment selection, though it remains relevant for epidemiologic purposes.

### Epidemiology

Approximately 58 million individuals are chronically infected worldwide, with roughly 2.4 million in the United States. The baby boomer cohort born between 1945 and 1965 accounts for 75% of US HCV cases, though universal screening is now recommended for all adults aged 18 years and older (USPSTF 2020, CDC 2020). The most common current route of transmission is injection drug use. Historical transmission through blood products occurred before 1992. Other transmission routes include needlestick injury, vertical transmission (5 to 8%), and sexual transmission, which is rare in heterosexual contacts but more common among men who have sex with men with HIV coinfection.

Following acute infection, spontaneous clearance occurs in 15 to 45% of patients, though anti-HCV antibodies persist and do not confer immunity. Among those who develop chronic infection (55 to 85%), 15 to 30% progress to cirrhosis over 20 to 30 years.

## Screening and Diagnosis

### Screening Recommendations (USPSTF 2020 / CDC 2020)

Universal screening is recommended for all adults aged 18 to 79 at least once, an approach expanded from the prior birth cohort strategy. Risk-based screening at any age applies to individuals with a history of injection drug use (ever), HIV infection, incarceration, hemodialysis, children of HCV-positive mothers, and those with needlestick exposure. Prenatal screening of all pregnant women during each pregnancy is recommended by the AASLD and IDSA (2023 guidance).

### Diagnostic Testing

The anti-HCV antibody serves as the screening test and indicates exposure, whether current or past. HCV RNA, available as a qualitative (detected or not detected) or quantitative assay, confirms active infection. Reflex testing, in which a positive anti-HCV result automatically triggers HCV RNA testing, streamlines the diagnostic pathway. A detected HCV RNA indicates active infection and warrants treatment evaluation. An anti-HCV positive result with negative RNA indicates either past resolved infection or a false-positive antibody.

### Pretreatment Assessment

Genotyping is still recommended by most guidelines, although pangenotypic regimens have reduced its importance for treatment selection. Fibrosis staging is essential, as it determines treatment duration, the need for HCC screening, and the urgency of treatment. Non-invasive methods include the FIB-4 index (incorporating age, AST, ALT, and platelets), where a value below 1.45 indicates low risk and above 3.25 indicates advanced fibrosis, and vibration-controlled transient elastography (FibroScan), where values below 9.5 kPa correspond to F0 to F2 and above 12.5 kPa to F3 to F4. Liver biopsy is rarely needed and is reserved for discordant non-invasive results or suspected concomitant liver disease.

Baseline laboratory evaluation should include HBV serologies (given the risk of reactivation during DAA therapy), HIV status, CBC, comprehensive metabolic panel, and INR. Screening for HBV coinfection is mandatory, as HBV reactivation can occur during or after DAA therapy, a risk acknowledged by a boxed warning.

## Direct-Acting Antiviral (DAA) Regimens

### Pangenotypic Regimens (Preferred)

| Regimen | Components | Duration | SVR Rate | Decompensated Cirrhosis | CKD (eGFR <30) | Key Interactions |
|---|---|---|---|---|---|---|
| SOF/VEL (Epclusa) | NS5B + NS5A inhibitor | 12 weeks | 95-99% | Yes (±RBV) | Avoid (sofosbuvir accumulation) | PPIs reduce VEL absorption; avoid strong P-gp inducers |
| GLE/PIB (Mavyret) | NS3/4A + NS5A inhibitor | 8 weeks (no cirrhosis); 12 weeks (cirrhosis) | 97-99% | Contraindicated (PI component) | Preferred (no renal adjustment) | Avoid atazanavir, strong CYP3A inducers |
| SOF/VEL/VOX (Vosevi) | NS5B + NS5A + NS3/4A | 12 weeks | 95-97% | Contraindicated (PI component) | Avoid | For DAA-experienced (prior NS5A failure) |

#### Sofosbuvir/Velpatasvir (Epclusa)

Sofosbuvir 400 mg and velpatasvir 100 mg are combined in a single tablet taken once daily for 12 weeks. The regimen is effective across genotypes 1 through 6, achieving SVR rates of 95 to 99%. It can be used in decompensated cirrhosis (Child-Pugh B and C), ideally without ribavirin when possible, though ribavirin may be added for compensated cirrhosis with baseline NS5A resistance-associated substitutions. Strong P-glycoprotein inducers (rifampin, carbamazepine, phenytoin, and St. John's wort) must be avoided. Proton pump inhibitors reduce velpatasvir absorption, and omeprazole should be limited to a maximum of 20 mg, taken 4 hours before the sofosbuvir/velpatasvir dose.

#### Glecaprevir/Pibrentasvir (Mavyret)

Glecaprevir 300 mg and pibrentasvir 120 mg are administered as three tablets taken once daily. The regimen is effective across genotypes 1 through 6, achieving SVR rates of 97 to 99%. For treatment-naive patients without cirrhosis, an 8-week course represents the shortest available DAA regimen. Treatment-naive patients with compensated cirrhosis require 12 weeks, and some treatment-experienced patients require 16 weeks. This regimen is contraindicated in decompensated cirrhosis (Child-Pugh B and C) because of its protease inhibitor component. Strong CYP3A inducers and atazanavir should be avoided.

#### Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi)

This triple combination targets NS5B, NS5A, and NS3/4A simultaneously. It is administered for 12 weeks and is primarily indicated for DAA-experienced patients, particularly those who failed prior NS5A inhibitor therapy. It achieves SVR rates of 95 to 97% in DAA-experienced patients across genotypes 1 through 6. Like other protease inhibitor-containing regimens, it is contraindicated in decompensated cirrhosis.

### Treatment Duration Summary

Treatment-naive patients without cirrhosis receive glecaprevir/pibrentasvir for 8 weeks or sofosbuvir/velpatasvir for 12 weeks. Treatment-naive patients with compensated cirrhosis receive either regimen for 12 weeks. Decompensated cirrhosis (Child-Pugh B or C) is treated with sofosbuvir/velpatasvir with or without ribavirin for 12 weeks. DAA-experienced patients with prior NS5A failure receive sofosbuvir/velpatasvir/voxilaprevir for 12 weeks.

### SVR (Sustained Virologic Response)

Sustained virologic response is defined as undetectable HCV RNA at 12 or more weeks after treatment completion (SVR12) and is equivalent to virologic cure. Relapse after SVR12 occurs in less than 1% of patients. Current DAA regimens achieve SVR in more than 95% of all patients.

<image>A treatment selection algorithm for hepatitis C in the DAA era. Start at top with "Confirmed HCV viremia (HCV RNA detected)." First assessment: "Assess fibrosis (FIB-4, FibroScan or biopsy) and check HBV serologies." Decision point: "Decompensated cirrhosis (Child-Pugh B or C)?" If yes: "SOF/VEL +/- ribavirin x 12 weeks (NO protease inhibitor-containing regimens); refer to transplant center." If no: "Compensated (no cirrhosis or Child-Pugh A)." Next decision: "Treatment-naive or experienced?" Treatment-naive without cirrhosis: "GLE/PIB x 8 weeks (shortest) OR SOF/VEL x 12 weeks." Treatment-naive with compensated cirrhosis: "GLE/PIB x 12 weeks OR SOF/VEL x 12 weeks." DAA-experienced (prior NS5A failure): "SOF/VEL/VOX x 12 weeks (if no decompensation) OR SOF/VEL + RBV x 24 weeks if decompensated." Include an "SVR12 check" box: "HCV RNA at 12 weeks post-treatment; if undetectable = CURED." Add a "Drug interactions" warning box listing key interactions: PPIs reduce velpatasvir absorption, strong P-gp/CYP3A inducers contraindicated, amiodarone + sofosbuvir = risk of symptomatic bradycardia. Use green for preferred regimens, yellow for alternatives, red for contraindications.</image>

## Special Populations

### Decompensated Cirrhosis

Only NS5A plus NS5B combinations (sofosbuvir/velpatasvir) should be used in decompensated cirrhosis; protease inhibitors must be avoided due to hepatotoxicity. Weight-based ribavirin, if tolerated, improves SVR by 5 to 10%, though erythropoietin may be needed for ribavirin-induced anemia. SVR may improve hepatic function, with 30 to 50% of patients showing MELD improvement and some being delisted from the transplant waiting list. HCC screening must continue indefinitely even after SVR.

### HBV/HCV Coinfection

HBV reactivation during or after DAA-induced HCV clearance occurs because HCV suppresses HBV replication, and when HCV is eliminated, HBV rebounds. All HCV patients must be screened for HBV (HBsAg, anti-HBc, anti-HBs) before initiating DAA therapy. HBsAg-positive patients should start HBV prophylaxis with entecavir or TDF before or concurrently with DAA therapy, continuing for 12 weeks after DAA completion. For anti-HBc-positive, HBsAg-negative patients, monitoring HBV DNA and ALT during and after DAA is recommended, though the choice between prophylaxis and monitoring remains debated.

### HIV/HCV Coinfection

HCV in HIV-coinfected patients is treated with the same DAA regimens as in monoinfection. Drug-drug interactions with antiretroviral therapy, particularly protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and cobicistat, must be carefully evaluated. SVR rates with DAAs are equivalent to those in HCV monoinfection.

### Chronic Kidney Disease (eGFR <30)

Glecaprevir/pibrentasvir is the preferred regimen in severe CKD, as it requires no renal dose adjustment and is not renally eliminated. Sofosbuvir-based regimens were previously avoided in severe CKD due to sofosbuvir accumulation, though some centers now use them with monitoring. Hemodialysis patients should receive glecaprevir/pibrentasvir for 8 or 12 weeks.

### Pregnancy

DAAs are not recommended during pregnancy due to insufficient safety data. Women of childbearing age should ideally be treated before pregnancy. Ribavirin is absolutely contraindicated in pregnancy because of its teratogenicity, and effective contraception is required during treatment and for 6 months after completion.

### Acute HCV

Acute HCV is defined as new HCV RNA positivity within 6 months of exposure. Observation for 12 to 16 weeks may be reasonable, as 15 to 45% of patients clear the virus spontaneously. If infection persists, treatment with DAAs using the same regimens is indicated. Some guidelines suggest shorter courses (for example, sofosbuvir/velpatasvir for 8 weeks for acute HCV without cirrhosis), though 12 weeks remains the standard.

## Post-SVR Management

### HCC Risk After SVR

SVR significantly reduces but does not eliminate hepatocellular carcinoma risk, with a 68 to 76% reduction. Patients with advanced fibrosis or cirrhosis at the time of SVR retain a continued HCC risk of 1 to 2% per year. HCC screening with ultrasound with or without alpha-fetoprotein every 6 months must continue indefinitely for all patients with advanced fibrosis (F3) or cirrhosis. Patients with F0 to F2 fibrosis at SVR have a very low HCC risk, and routine HCC screening is not needed for this group.

### Liver Disease After SVR

Fibrosis regression occurs in the majority of patients, with 68% improving by at least one stage over 5 years. Cirrhosis may regress to non-cirrhotic fibrosis, though architectural distortion may persist. Portal hypertension may also persist even with SVR, and variceal screening should be maintained for patients who were cirrhotic at baseline. No further HCV monitoring is needed, as SVR12 represents a durable cure in more than 99% of patients.

### Reinfection

SVR does not confer immunity to reinfection. The reinfection risk in individuals with ongoing injection drug use is 1 to 8% per year. Annual monitoring with HCV RNA is recommended in high-risk populations, including people who inject drugs and men who have sex with men with HIV. Reinfection can be retreated with DAAs.

<image>A post-SVR monitoring guide displayed as a timeline and decision tree. Start with "SVR12 confirmed (HCV RNA undetectable >= 12 weeks post-treatment)." Assessment: "Fibrosis stage at time of treatment." Two main pathways: (1) "F0-F2 (no advanced fibrosis)": "No routine HCC screening needed. HCV RNA check only if new risk exposure or unexplained ALT elevation. Annual health maintenance. Patient is CURED." (2) "F3-F4 (advanced fibrosis/cirrhosis)": "Continue HCC screening (US +/- AFP q6 months) INDEFINITELY. Continue variceal screening per guidelines if cirrhosis. Annual assessment of liver function and fibrosis regression (FibroScan, FIB-4). Monitor for reinfection if ongoing risk behaviors (HCV RNA annually)." Include statistics in info boxes: "SVR reduces HCC risk by 68-76% but does not eliminate it. Fibrosis regression occurs in 68% over 5 years. Reinfection rate in PWID: 1-8%/year — SVR does not confer immunity." Use green for cured/low-risk pathway, yellow for continued monitoring pathway. Include a reminder: "No further routine HCV RNA monitoring needed after SVR12 in low-risk patients — the cure is durable (>99%)."</image>

## Drug Resistance and Retreatment

### Resistance-Associated Substitutions (RAS)

Pre-existing resistance-associated substitutions may affect certain regimens, with the NS5A RAS Y93H being particularly relevant for sofosbuvir/velpatasvir in genotype 3 patients with cirrhosis. Baseline RAS testing is not routinely required for treatment-naive patients. RAS testing should be considered for genotype 3 patients with cirrhosis when using sofosbuvir/velpatasvir and for patients with prior DAA failure.

### Retreatment After DAA Failure

DAA failure occurs in fewer than 5% of patients with current regimens. Sofosbuvir/velpatasvir/voxilaprevir for 12 weeks is the preferred retreatment for most scenarios. Sofosbuvir combined with glecaprevir/pibrentasvir for 12 to 16 weeks is an alternative. For decompensated cirrhosis patients who failed prior DAA therapy, sofosbuvir/velpatasvir with ribavirin for 24 weeks is the recommended approach.

## Simplified HCV Treatment (CDC/AASLD 2023)

The simplified treatment pathway is designed for treatment-naive adults without cirrhosis or with compensated cirrhosis. It requires minimal pretreatment testing: anti-HCV, HCV RNA, HBV serologies, basic metabolic panel, and CBC. Genotyping may be omitted when using a pangenotypic regimen, and fibrosis assessment may be simplified to FIB-4 alone. The goal is to expand HCV treatment delivery to primary care and non-specialist settings, reducing barriers to cure. This approach aligns with the WHO elimination target of 90% of cases diagnosed and 80% treated by 2030.

## Key Clinical Pearls
- DAA therapy achieves SVR (cure) in >95% of all HCV patients regardless of genotype, including those with compensated cirrhosis
- GLE/PIB for 8 weeks is the shortest regimen for treatment-naive patients without cirrhosis
- Protease inhibitor-containing regimens (GLE/PIB, SOF/VEL/VOX) are CONTRAINDICATED in decompensated cirrhosis (Child-Pugh B/C)
- Screen ALL HCV patients for HBV before DAA therapy — HBV reactivation (including fatal cases) is documented during HCV treatment
- Continue HCC screening indefinitely after SVR in patients with F3-F4 fibrosis — SVR reduces but does not eliminate HCC risk
- PPIs reduce velpatasvir absorption — use omeprazole <=20 mg, taken 4 hours before SOF/VEL
- SVR does NOT confer immunity — reinfection occurs in 1-8% per year in high-risk populations; annual HCV RNA monitoring recommended in PWID
- Simplified treatment algorithms enable HCV cure delivery in primary care settings — essential for achieving WHO 2030 elimination targets

## References
1. Ghany MG, et al. Hepatitis C guidance 2019 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. *Hepatology*. 2020;71(2):686-721.
2. AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. www.hcvguidelines.org (continuously updated).
3. Feld JJ, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection (ASTRAL-1). *N Engl J Med*. 2015;373(27):2599-2607.
4. Zeuzem S, et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection (ENDURANCE-1/3). *N Engl J Med*. 2018;378(4):354-369.
5. Carrat F, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study (ANRS CO22 HEPATHER). *Lancet Infect Dis*. 2019;19(7):768-779.